Anastrozol Bluefish

Quick links

Choose a section

Quick links to important sections

Advertisements

Anastrozol Bluefish

Advertisements
Advertisements

Overview of Anastrozol Bluefish

Quick Facts

Property Description
Active ingredient Anastrozole
Form Tablets (Oral administration)
Pharmacological class Selective Non-Steroidal Aromatase Inhibitor
Common Use Hormonal/Endocrine Therapy
Origin Synthetic 1,2,4-Triazole Derivative

What is Anastrozol Bluefish?

Anastrozol Bluefish: Definition and Pharmacological Classification

Anastrozol Bluefish is a prescription-only, generic medicine manufactured by Bluefish Pharma. Its sole active ingredient is Anastrozole. This medication is classified as a selective non-steroidal aromatase inhibitor, positioning it within the broader group of antineoplastic agents used for hormonal therapy. The formulation is presented as tablets intended for oral administration.

Its classification is crucial as it dictates the drug's specialized role, which is clinically recognized for its part in managing hormone-sensitive conditions. As a generic, it provides the identical therapeutic benefit as the original compound, focusing specifically on the hormonal cascade.

Composition, Origin, and Therapeutic Type

The active compound, Anastrozole, is a synthetic 1,2,4-triazole derivative distinguished by its non-steroidal structure. Anastrozol Bluefish is a single-ingredient product, comprising Anastrozole and the necessary pharmaceutical excipients for its solid oral dosage form.

This drug is categorized as endocrine (hormonal) targeted therapy, which focuses on modifying hormone activity within the body. Pharmacological studies confirm the compound’s mechanism of suppressing a specific enzyme, making it a critical treatment for adult patients, particularly postmenopausal women, whose estrogen production relies heavily on this pathway.

High-Level Purpose: Suppression of Estrogen

The fundamental purpose of Anastrozol Bluefish is to achieve significant estrogen biosynthesis suppression. It works by competitively blocking the aromatase enzyme, which is responsible for converting androgen hormones into estrogen in peripheral tissues. By inhibiting this critical enzyme, the medication dramatically lowers the level of circulating estrogen concentrations in the bloodstream. This targeted physiological action forms the basis of its therapeutic use, providing a specific mechanism to mitigate the growth stimulation of tissues sensitive to estrogen.

Regulatory References

  1. MedlinePlus: Anastrozole
Advertisements

What side effects are possible with Anastrozol Bluefish?

Possible Side Effects and Safety Information

The safety profile of Anastrozol Bluefish is based on clinical trial data and post-marketing experience, with adverse reactions generally categorized by frequency (Very Common, Common, Uncommon, Rare, Very Rare).

Very Common Adverse Reactions (May affect more than 1 in 10 people) are typically related to the reduction of estrogen levels. These include hot flushes, pain in joints (arthralgia), stiffness and arthritis, asthenia (feeling weak), headache, and nausea.

Frequency Category Selected Adverse Reactions (Examples)
Very Common (ge 1/10) Hot flushes, arthralgia/joint pain, asthenia, headache, nausea, osteoporosis, depression
Common (ge 1/100 to <1/10) Loss of appetite, hypercholesterolaemia, carpal tunnel syndrome, diarrhoea, vomiting, hair loss (alopecia), vaginal bleeding/dryness, bone pain

Clinically Significant and Serious Reactions

Decreases in bone mineral density leading to osteoporosis and an increased risk of fractures are recognized long-term effects requiring monitoring. Increases in total cholesterol may also occur.

Serious, though rare, adverse reactions have been documented, including severe hypersensitivity reactions such as angioedema (swelling of the face, tongue, or throat with difficulty breathing), Stevens-Johnson syndrome (a severe skin reaction), and hepatitis (liver inflammation). An increased incidence of ischemic cardiovascular events has been noted in women with pre-existing heart disease.

Safety Restrictions

Anastrozol Bluefish is contraindicated in women who are premenopausal, pregnant, or breast-feeding. It may cause fetal harm and is classified as toxic to reproduction. Caution is advised for patients with existing ischemic heart disease, hypercholesterolaemia, and pre-existing osteoporosis.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that the single dose of Anastrozol Bluefish that results in life-threatening symptoms has not been established in humans. Clinical experience with accidental overdosage is limited; however, high doses reported in clinical trials, including single doses up to 60 mg, were observed to be well tolerated.

Regulatory Mandates for Emergency Action

If overdosage is suspected, it is mandatory to seek emergency medical attention immediately. Regulatory guidance emphasizes that the management must be symptomatic and consist of general supportive care. This approach is required because the official labeling explicitly states that no specific antidote is known for Anastrozole.

Officially Documented Management

Procedures described in official regulatory documents include close observation of the patient and frequent monitoring of vital signs. For potential decontamination, vomiting may be induced if the patient remains alert. Furthermore, due to the drug’s characteristic low protein binding, dialysis may be helpful in elimination. Healthcare professionals are also advised to consider the possibility that multiple agents may have been taken when managing the overdose event.

Advertisements

Therapeutic Uses of Anastrozol Bluefish

What Anastrozol Bluefish Treats: Main Uses and Benefits

Anastrozol Bluefish is a medicine indicated for the management of breast cancer in post-menopausal women. Its purpose is to reduce the levels of oestrogen in the body, which helps influence the growth of tumours that are sensitive to this hormone.

The clinical scenarios where this medicine may be used include:

  • The follow-up treatment of hormone receptor-positive early invasive breast cancer.
  • The treatment of advanced breast cancer in women who have the disease with positive oestrogen or progesterone receptors.
  • The follow-up treatment of early breast cancer in women who have received prior management with tamoxifen for a period of two to three years.

This medication offers a treatment option for a serious health condition, supporting overall disease management.

“The drug provides an approved option in the management sequence for hormone-sensitive disease.”


Quick Fact: Focus on adjuvant and advanced breast cancer management

Advertisements

Eligibility and Restrictions for Use

Official Eligibility for Anastrozol Bluefish Use

Anastrozol Bluefish is officially designated for use exclusively by postmenopausal women, encompassing the adult and elderly population. This eligibility status is mandatory and reflects the drug's specialized context.

Use is absolutely contraindicated in all premenopausal women, including women who are pregnant or breastfeeding. Absolute prohibitions also apply to patients with known hypersensitivity to anastrozole or any excipients, as well as those with inherited disorders such as galactose intolerance or lactase deficiency.

For other populations, use is conditional or restricted. The medicine is not recommended for children and adolescents, as regulatory authorities have not established its safety and efficacy in these age groups. Caution is required for patients with severe renal impairment or moderate to severe hepatic impairment, with treatment dependent on a benefit-risk assessment. Furthermore, women with a pre-existing risk of osteoporosis must undergo a formal bone mineral density assessment prior to treatment.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Anastrozol Bluefish is based on specific mandatory restrictions and the classification of pharmacokinetic interactions as documented in official regulatory sources.

Formal Interaction Restrictions

Co-administration with oestrogen-containing therapies is formally contraindicated because these substances would negate the pharmacological action of Anastrozol Bluefish (pharmacodynamic antagonism). The medicine should not be administered concurrently with Tamoxifen due to the formal restriction citing a reduction in anastrozole plasma concentration by approximately 27% (a pharmacokinetic effect) and a diminished expected activity. Furthermore, co-administration with LHRH analogues (e.g., Goserelin) is not supported by safety data and is restricted from use outside of clinical trial settings.

Metabolic and Clearance Documentation

Official studies involving CYP substrates like Warfarin and Antipyrine conclude that co-administration with other medicines is unlikely to result in clinically significant CYP-mediated drug interactions at the recommended dose. Regarding administration conditions, food does not affect the extent of drug absorption (AUC), meaning the medicine can be taken with or without food.

Population-Specific Notes

Documentation indicates that in patients with stable hepatic cirrhosis (mild-to-moderate impairment), the apparent oral clearance of Anastrozole is reduced by approximately 30%. This alteration in clearance results in a documented status of potentially increased drug exposure in this specific population.

Advertisements

Mechanism of Action

Anastrozole functions as a selective non-steroidal competitive inhibitor targeting the aromatase enzyme (CYP19A1). This drug achieves its effect by reversibly binding to the enzyme’s heme iron atom within peripheral tissues. This molecular interaction prevents the enzyme from performing its core function: the aromatization of androgen precursors into estrogens (Estradiol and Estrone).

This competitive blockade interrupts the final step of the Estrogen Biosynthesis Pathway, initiating a physiological cascade that leads to a profound and sustained reduction (typically over 85%) in the concentration of circulating estrogens. This systemic shift in the hormonal environment constitutes the basis of the drug's physiological action. The mechanism is highly selective, preserving adrenal corticosteroid production. However, its suppressive effect is minimal when ovarian estrogen production is active, and it is subject to pharmacodynamic antagonism if exogenous estrogens are introduced.

Advertisements

Dosage and Administration Information

Official Administration Guidelines: How to Use Anastrozol Bluefish

Anastrozol Bluefish is an oral solid dosage form that is used according to a fixed daily regimen. The use of the medication is standardized across all approved indications.


Entity Official Instruction
Route of Administration Oral (by mouth)
Dosing Schedule One 1 mg tablet
Frequency Pattern Once daily (qDay)
Timing in Relation to Meals May be taken with or without food
Preparation Swallow the tablet whole; no crushing or chewing

Procedural and Duration Requirements

The established usage protocol requires taking one 1 mg tablet once a day, with flexibility regarding the time of day and its relationship to meals. This standardized dose is generally maintained for older adults and patients with mild-to-moderate renal or mild hepatic impairment, as no dosage adjustment is officially recommended for these groups.

If a dose is missed, the protocol is to skip the missed dose if it is near the time for the next dose, and then simply resume the regular one-tablet-per-day schedule; doses should not be doubled to compensate for a forgotten one.

Treatment duration is defined by the clinical context. For adjuvant use following initial therapy, the course is typically five years. For advanced cancer management, administration is generally continued until objective disease progression is confirmed.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence Overview

Research has evaluated Anastrozol Bluefish as a component of hormone-sensitive breast cancer treatment, primarily in postmenopausal women. The evidence base includes large-scale Phase III Randomized Controlled Trials (RCTs) that have helped establish the drug's role in the adjuvant (post-surgery) setting.


Clinical Trial Findings

Studies have been conducted to investigate the drug's effect in early-stage, hormone receptor-positive breast cancer, as well as in advanced or metastatic disease. Key areas of investigation include:

  • Long-Term Follow-up: Ongoing analysis of original clinical trial cohorts (e.g., the Arimidex, Tamoxifen, Alone or in Combination - ATAC trial) continues to investigate the long-term changes in symptoms and overall outcomes years after treatment has been stopped.
  • Extended Adjuvant Therapy: Research has explored the duration of therapy, with studies examining whether continuing treatment beyond the standard five years is associated with different recurrence rates.
  • Combination Therapies: Recent research has focused on the use of anastrozole in combination with newer targeted agents, such as CDK4/6 inhibitors, to evaluate the association between these combinations and patient progression-free survival in metastatic settings.

Safety and Research Gaps

Studies consistently report that common findings related to the drug's use include joint pain, hot flashes, and a potential reduction in bone mineral density. Research in this area is ongoing to:

  • Identify Predictive Markers: Studies are exploring genetic or clinical factors that may be associated with adherence to treatment and the development of specific side effects.
  • Manage Bone Health: Research continues to investigate optimal co-interventions, such as the use of bisphosphonates, to manage the effect of reduced estrogen levels on bone density.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Anastrozol Bluefish (FAQ)


Q: How quickly does Anastrozol Bluefish start to work after you begin taking it?

Official pharmacokinetic studies show that Anastrozole begins working very quickly to reduce the level of estrogen in the body. Typically, serum estradiol is reduced significantly within 24 hours of taking the first tablet. This long-lasting effect is consistent with its prescribed once-daily use.


Q: Can men take Anastrozol Bluefish for conditions other than breast cancer?

According to official drug information, Anastrozol Bluefish is approved exclusively for the treatment of hormone receptor-positive breast cancer in women who are postmenopausal. Its use for other conditions, including in men or in paediatric populations, is not an official, approved indication by regulatory agencies.


Q: Is it okay to drink alcohol while using Anastrozol Bluefish?

Official patient resources state that consuming small amounts of alcohol does not appear to negatively affect the drug's safety or how well it works. Some official patient resources note that limiting alcohol may assist with managing menopausal-type side effects, such as hot flashes.


Q: Is Anastrozol Bluefish known to cause weight gain?

Some patient information lists weight gain as a possible finding associated with the drug’s use. However, evidence from large clinical trials comparing Anastrozole to other treatments did not find a statistically significant difference in weight changes between the groups. This suggests that weight changes, if experienced, may not be directly attributable to the drug itself.


Q: Is Anastrozol Bluefish used to treat other types of cancer besides breast cancer?

Official regulatory documents confirm that Anastrozole is only approved for the treatment of hormone receptor-positive breast cancer in women who are postmenopausal. Its use for any other type of cancer is not supported by current approved indications.


Q: If I stop taking Anastrozol Bluefish, will the side effects go away immediately?

The drug has an elimination half-life of approximately 50 hours, meaning it generally takes several days for the medicine to be fully cleared from the body. Side effects linked directly to low estrogen, such as hot flashes, may begin to resolve within a few weeks. However, documented effects like decreased bone mineral density may persist and are generally subject to ongoing clinical monitoring.


Q: Is it safe to drive or operate machinery while taking Anastrozol Bluefish?

Official product information states that Anastrozole is unlikely to impair the ability to drive or operate machinery. However, because some users report side effects such as asthenia (feeling weak or low energy) and somnolence (drowsiness), official product information suggests caution when engaging in activities requiring full attention.


Q: What happens if I accidentally take two Anastrozol Bluefish tablets instead of one?

Regulatory guidance advises that there is no specific antidote for taking more than the prescribed dose. If an overdose is suspected, official instructions advise that immediate medical attention is necessary. Treatment would be focused on managing any symptoms that appear.


Q: Is there a link between Anastrozol Bluefish and vision problems?

Official safety data indicates that, although it is uncommon, vision changes, including blurred vision, have been reported as a potential side effect. Official documents state that any sudden changes in vision should be reported to a healthcare provider promptly.


Q: Are there different long-term outcomes for people who take Anastrozol Bluefish versus letrozole?

Anastrozole and Letrozole are two different medications within the same class (aromatase inhibitors). Reviews of clinical data indicate that there are generally no major differences in clinical effectiveness or long-term outcomes between the two drugs. Some studies have noted a slight difference in estrogen-suppressing potency; however, the clinical importance of this is generally considered unclear in regulatory contexts.


Q: Can Anastrozol Bluefish be used to prevent breast cancer in high-risk individuals?

Official regulatory approvals designate Anastrozole as a treatment for existing hormone receptor-positive breast cancer. It is not currently approved by regulatory agencies for the purpose of preventing breast cancer (chemoprevention) in high-risk individuals, even though it has been studied in that context.

Advertisements

How should Anastrozol Bluefish be stored and disposed of?

Storage and Disposal Requirements

Anastrozole tablets must be stored according to mandatory conditions defined in the official labeling to ensure product stability and safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature (20 C to 25 C, or 68 F to 77 F).
Container Keep in the original container and keep the container tightly closed.
Handling Must be kept out of the sight and reach of children.

Storage environments outside of this specified temperature range, such as refrigeration or freezing, are prohibited. The medicine must not be used past the expiration date printed on the package.

Disposal Instructions

Disposal of unused or expired Anastrozole tablets must strictly follow local regulatory requirements for pharmaceutical waste, such as authorized drug take-back programs. The product should not be disposed of in household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anastrozol Bluefish found in:

A-Z Index: